Last reviewed · How we verify

NK-1R antagonist — Competitive Intelligence Brief

NK-1R antagonist (NK-1R antagonist) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NK-1 receptor antagonist. Area: Oncology, Gastroenterology, Pain Management.

phase 3 NK-1 receptor antagonist NK-1R (Neurokinin-1 receptor) Oncology, Gastroenterology, Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

NK-1R antagonist (NK-1R antagonist) — Prof. Dr. Fridoon Jawad Ahmad. NK-1R antagonists block neurokinin-1 receptors to inhibit substance P signaling, reducing nausea, vomiting, and pain perception.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NK-1R antagonist TARGET NK-1R antagonist Prof. Dr. Fridoon Jawad Ahmad phase 3 NK-1 receptor antagonist NK-1R (Neurokinin-1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NK-1 receptor antagonist class)

  1. Prof. Dr. Fridoon Jawad Ahmad · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NK-1R antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/nk-1r-antagonist. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: